Quanticate Demonstrates New Outsourcing Strategy and Helpdesk at DIA 2011
Quanticate announces its new Centralized Clinical Data Sciences, an outsourcing strategy at this year’s 47th Annual DIA (Drug Information Association) Meeting, occurring in Chicago from June 19-23.
“Based on Quanticate’s 10-plus years of outsourcing and extensive clinical trial experience, this is an advancement in outsourcing that Quanticate is well placed to deliver. It has benefits in trial design and provides an efficient use of database design. Our outsourcing model can also leverage the latest technologies in cloud computing as well as ensure global regulatory compliance,” said David Underwood, CEO of Quanticate.
Centralized Clinical Data Sciences further develops strategic alliances and functional service provision and allows for easy combining of data from different studies within and across Phases.
In addition to the new outsourcing model, Quanticate is launching a Statistical Consultancy Helpdesk, an online resource that will provide easy access to expert Statistical Consultancy. Either via a dedicated phone line or the Internet, customers will be able to access the helpdesk with ease.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
